Status:
UNKNOWN
Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
This is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the PD-1 antibody tirelizumab combined with chemotherapy monotherapy in patients wit...
Detailed Description
This is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the PD-1 antibody tirellizumab combined with chemotherapy monotherapy in patients wi...
Eligibility Criteria
Inclusion
- Pathologically confirmed recurrent/metastatic non-small cell lung cancer with local recurrence or distant metastasis after prior radiotherapy and/or surgery, or with distant metastasis at the time of admission.
- The age range is between 18 and 85.
- Predicted survival ≥12 weeks.
Exclusion
- Patients with other malignant tumors.
- Positive tests for EGFR mutation and ALK fusion gene have been confirmed.
- Partial comorbidity.
- other.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT05965102
Start Date
August 1 2023
End Date
June 1 2025
Last Update
July 28 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.